Liver fatty acid binding protein (L-FABP) as a target for the prevention of high fat diet induced obesity and hepatic steatosis

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 9, Issue 1, 2009, Pages 30-37

  Newberry, Elizabeth P ^a   Davidson, Nicholas O ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diet induced obesity; Fatty acid metabolism; Hepatic steatosis; Non alcoholic fatty liver disease

Indexed keywords

FATTY ACID BINDING PROTEIN; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID;

ARTICLE; CHOLESTEROL METABOLISM; FATTY ACID TRANSPORT; FATTY LIVER; FOOD INTAKE; GENE DELETION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE LOCATION; GENE TARGETING; LIPID DIET; NONHUMAN; OBESITY; PHENOTYPE;

EID: 70350014829     PISSN: 18715222     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152209788009805     Document Type: Article

References (60)

1. Batterham, R.L.; Cowley, M.A.; Small, C.J.; Herzog, H.; Cohen, M.A.; Dakin, C.L.; Wren, A.M.; Brynes, A.E.; Low, M.J.; Ghatei, M.A.; Cone, R.D.; Bloom, S.R. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature, 2002, 418(6898), 650-654.
2. Vrang, N.; Madsen, A.N.; Tang-Christensen, M.; Hansen, G.; Larsen, P.J. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2006, 291(2), R367-375.
3. Tschop, M.; Castaneda, T.R.; Joost, H.G.; Thone-Reineke, C.; Ortmann, S.; Klaus, S.; Hagan, M.M.; Chandler, P.C.; Oswald, K.D.; Benoit, S.C.; Seeley, R.J.; Kinzig, K.P.; Moran, T.H.; Becksickinger, A.G.; Koglin, N.; Rodgers, R.J.; Blundell, J.E.; Ishii, Y.; Beattie, A.H.; Holch, P.; Allison, D.B.; Raun, K.; Madsen, K.; Wulff, B.S.; Stidsen, C.E.; Birringer, M.; Kreuzer, O.J.; Schindler, M.; Arndt, K.; Rudolf, K.; Mark, M.; Deng, X.Y.; Whitcomb, D.C.; Halem, H.; Taylor, J.; Dong, J.; Datta, R.; Culler, M.; Craney, S.; Flora, D.; Smiley, D.; Heiman, M.L. Physiology: does gut hormone PYY3-36 decrease food intake in rodents? Nature, 2004, 430(6996), 1 p following 165; discussion 162 p following 165.
4. Boggiano, M.M.; Chandler, P.C.; Oswald, K.D.; Rodgers, R.J.; Blundell, J.E.; Ishii, Y.; Beattie, A.H.; Holch, P.; Allison, D.B.; Schindler, M.; Arndt, K.; Rudolf, K.; Mark, M.; Schoelch, C.; Joost, H.G.; Klaus, S.; Thone-Reineke, C.; Benoit, S.C.; Seeley, R.J.; Beck-Sickinger, A.G.; Koglin, N.; Raun, K.; Madsen, K.; Wulff, B.S.; Stidsen, C. E.; Birringer, M.; Kreuzer, O.J.; Deng, X.Y.; Whitcomb, D.C.; Halem, H.; Taylor, J.; Dong, J.; Datta, R.; Culler, M.; Ortmann, S.; Castaneda, T.R.; Tschop, M. PYY3-36 as an anti-obesity drug target. Obes. Rev., 2005, 6(4), 307-322.
5. Zhi, J.; Mulligan, T.E.; Hauptman, J.B. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J. Clin. Pharmacol., 1999, 39(1), 41-46.
6. Weibel, E.K.; Hadvary, P.; Hochuli, E.; Kupfer, E.; Lengsfeld, H. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J. Antibiot. (Tokyo), 1987, 40(8), 1081-1085.
7. Garcia-Calvo, M.; Lisnock, J.; Bull, H.G.; Hawes, B.E.; Burnett, D.A.; Braun, M.P.; Crona, J.H.; Davis, H.R. Jr.; Dean, D.C.; Detmers, P.A.; Graziano, M.P.; Hughes, M.; Macintyre, D.E.; Ogawa, A.; O'Neill, K.A.; Iyer, S.P.; Shevell, D.E.; Smith, M.M.; Tang, Y.S.; Makarewicz, A.M.; Ujjainwalla, F.; Altmann, S.W.; Chapman, K.T.; Thornberry, N.A. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA, 2005, 102(23), 8132-8137.
8. Altmann, S.W.; Davis, H.R. Jr.; Zhu, L.J.; Yao, X.; Hoos, L.M.; Tetzloff, G.; Iyer, S.P.; Maguire, M.; Golovko, A.; Zeng, M.; Wang, L.; Murgolo, N.; Graziano, M.P. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 2004, 303(5661), 1201-1204.
9. Chandler, C.E.; Wilder, D.E.; Pettini, J.L.; Savoy, Y.E.; Petras, S.F.; Chang, G.; Vincent, J.; Harwood, H.J. Jr. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J. Lipid Res., 2003, 44(10), 1887-1901.
10. Robl, J.A.; Sulsky, R.; Sun, C.Q.; Simpkins, L.M.; Wang, T.; Dickson, J.K. Jr.; Chen, Y.; Magnin, D.R.; Taunk, P.; Slusarchyk, W.A.; Biller, S.A.; Lan, S.J.; Connolly, F.; Kunselman, L.K.; Sabrah, T.; Jamil, H.; Gordon, D.; Harrity, T.W.; Wetterau, J.R. A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. J. Med. Chem., 2001, 44(6), 851-856.
11. Wetterau, J.R.; Gregg, R.E.; Harrity, T.W.; Arbeeny, C.; Cap, M.; Connolly, F.; Chu, C.H.; George, R.J.; Gordon, D.A.; Jamil, H.; Jolibois, K.G.; Kunselman, L.K.; Lan, S.J.; Maccagnan, T.J.; Ricci, B.; Yan, M.; Young, D.; Chen, Y.; Fryszman, O.M.; Logan, J.V.; Musial, C.L.; Poss, M.A.; Robl, J.A.; Simpkins, L.M.; Slusarchyk, W.A.; Sulsky, R.; Taunk, P.; Magnin, D.R.; Tino, J.A.; Lawrence, R.M.; Dickson, J.K. Jr.; Biller, S.A. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science, 1998, 282(5389), 751-754.
12. Gordon, J.I.; Elshourbagy, N.; Lowe, J.B.; Liao, W.S.; Alpers, D.H.; Taylor, J.M. Tissue specific expression and developmental regulation of two genes coding for rat fatty acid binding proteins. J. Biol. Chem., 1985, 260(4), 1995-1998.
13. Lowe, J.B.; Sacchettini, J.C.; Laposata, M.; McQuillan, J.J.; Gordon, J.I. Expression of rat intestinal fatty acid-binding protein in Escherichia coli. Purification and comparison of ligand binding characteristics with that of Escherichia coli-derived rat liver fatty acid-binding protein. J. Biol. Chem., 1987, 262(12), 5931-5937.
14. Thompson, J.; Winter, N.; Terwey, D.; Bratt, J.; Banaszak, L. The crystal structure of the liver fatty acid-binding protein. A complex with two bound oleates. J. Biol. Chem., 1997, 272(11), 7140-7150.
15. Thumser, A.E.; Wilton, D.C. The binding of cholesterol and bile salts to recombinant rat liver fatty acid-binding protein. Biochem. J., 1996, 320(Pt 3), 729-733.
16. Haunerland, N.; Jagschies, G.; Schulenberg, H.; Spener, F. Fatty-acid-binding proteins. Occurrence of two fatty-acid-binding proteins in bovine liver cytosol and their binding of fatty acids, cholesterol, and other lipophilic ligands. Hoppe Seylers Z Physiol. Chem., 1984, 365(3), 365-376.
17. Wolfrum, C.; Ellinghaus, P.; Fobker, M.; Seedorf, U.; Assmann, G.; Borchers, T.; Spener, F. Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein. J. Lipid Res., 1999, 40(4), 708-714.
18. Martin, G.G.; Huang, H.; Atshaves, B.P.; Binas, B.; Schroeder, F. Ablation of the liver fatty acid binding protein gene decreases fatty acyl CoA binding capacity and alters fatty acyl CoA pool distribution in mouse liver. Biochemistry, 2003, 42(39), 11520-11532.
19. Woodford, J.K.; Behnke, W.D.; Schroeder, F. Liver fatty acid binding protein enhances sterol transfer by membrane interaction. Mol. Cell Biochem., 1995, 152(1), 51-62.
20. Nemecz, G.; Schroeder, F. Selective binding of cholesterol by recombinant fatty acid binding proteins. J. Biol. Chem., 1991, 266(26), 17180-17186.
21. Luxon, B.A.; Milliano, M.T.; Weisiger, R.A. Induction of hepatic cytosolic fatty acid binding protein with clofibrate accelerates both membrane and cytoplasmic transport of palmitate. Biochim. Biophys. Acta, 2000, 1487(2-3), 309-318.
22. Murphy, E.J. L-FABP and I-FABP expression increase NBD-stearate uptake and cytoplasmic diffusion in L cells. Am. J. Physiol., 1998, 275(2 Pt 1), G244-249.
23. Wolfrum, C.; Buhlmann, C.; Rolf, B.; Borchers, T.; Spener, F. Variation of liver-type fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake. Biochim. Biophys. Acta, 1999, 1437(2), 194-201.
24. Bass, N.M. The cellular fatty acid binding proteins: aspects of structure, regulation, and function. Int. Rev. Cytol., 1988, 111, 143-184.
25. Brandes, R.; Kaikaus, R.M.; Lysenko, N.; Ockner, R.K.; Bass, N.M. Induction of fatty acid binding protein by peroxisome proliferators in primary hepatocyte cultures and its relationship to the induction of peroxisomal beta-oxidation. Biochim. Biophys. Acta, 1990, 1034(1), 53-61.
26. Wolfrum, C.; Borrmann, C.M.; Borchers, T.; Spener, F. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha - and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc. Natl. Acad. Sci. USA, 2001, 98(5), 2323-2328.
27. Huang, H.; Starodub, O.; McIntosh, A.; Atshaves, B.P.; Woldegiorgis, G.; Kier, A.B.; Schroeder, F. Liver fatty acid-binding protein colocalizes with peroxisome proliferator activated receptor alpha and enhances ligand distribution to nuclei of living cells. Biochemistry, 2004, 43(9), 2484-2500.
28. Newberry, E.P.; Xie, Y.; Kennedy, S.; Han, X.; Buhman, K.K.; Luo, J.; Gross, R.W.; Davidson, N.O. Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J. Biol. Chem., 2003, 278(51), 51664-51672.
29. Martin, G.G.; Danneberg, H.; Kumar, L.S.; Atshaves, B.P.; Erol, E.; Bader, M.; Schroeder, F.; Binas, B. Decreased liver fatty acid binding capacity and altered liver lipid distribution in mice lacking the liver fatty acid-binding protein gene. J. Biol. Chem., 2003, 278(24), 21429-21438.
30. Martin, G.G.; Atshaves, B.P.; McIntosh, A.L.; Mackie, J.T.; Kier, A.B.; Schroeder, F. Liver fatty acid-binding protein gene-ablated female mice exhibit increased age-dependent obesity. J. Nutr., 2008, 138(10), 1859-1865.
31. Newberry, E.P.; Xie, Y.; Kennedy, S.M.; Luo, J.; Davidson, N. O. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology, 2006, 44(5), 1191-1205.
32. Martin, G.G.; Atshaves, B.P.; McIntosh, A.L.; Mackie, J.T.; Kier, A.B.; Schroeder, F. Liver fatty acid binding protein gene ablation potentiates hepatic cholesterol accumulation in cholesterol-fed female mice. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290(1), G36-48.
33. Martin, G.G.; Atshaves, B.P.; McIntosh, A.L.; Mackie, J.T.; Kier, A.B.; Schroeder, F. Liver fatty-acid-binding protein (L-FABP) gene ablation alters liver bile acid metabolism in male mice. Biochem. J., 2005, 391(Pt 3), 549-560.
34. Newberry, E.P.; Kennedy, S.M.; Xie, Y.; Sternard, B.T.; Luo, J.; Davidson, N.O. Diet-induced obesity and hepatic steatosis in L-Fabp/ mice is abrogated with SF, but not PUFA, feeding and attenuated after cholesterol supplementation. Am. J. Physiol. Gastrointest. Liver. Physiol., 2008, 294(1), G307-314.
35. Newberry, E.P.; Kennedy, S.M.; Xie, Y.; Luo, J.; Davidson, N.O. Diet-induced alterations in intestinal and extrahepatic lipid metabolism in liver fatty acid binding protein knockout mice. Mol. Cell Biochem., 2008.
36. Xie, Y.; Newberry, E.P.; Kennedy, S.M.; Luo, J.; Davidson, N.O. Increased susceptibility to diet-induced gallstones in liver fatty acid binding protein (L-Fabp) knockout mice. J. Lipid Res., 2009.
37. Nemecz, G.; Hubbell, T.; Jefferson, J.R.; Lowe, J.B.; Schroeder, F. Interaction of fatty acids with recombinant rat intestinal and liver fatty acid-binding proteins. Arch. Biochem. Biophys., 1991, 286(1), 300-309.
38. Neeli, I.; Siddiqi, S.A.; Siddiqi, S.; Mahan, J.; Lagakos, W.S.; Binas, B.; Gheyi, T.; Storch, J.; Mansbach, C.M., 2nd. Liver fatty acid-binding protein initiates budding of pre-chylomicron transport vesicles from intestinal endoplasmic reticulum. J. Biol. Chem., 2007, 282(25), 17974-17984.
39. Hussain, M.M.; Shi, J.; Dreizen, P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J. Lipid Res. 2003, 44(1), 22-32.
40. Davidson, N.O.; Shelness, G.S. APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu. Rev. Nutr., 2000, 20, 169-193.
41. Spann, N.J.; Kang, S.; Li, A.C.; Chen, A.Z.; Newberry, E.P.; Davidson, N.O.; Hui, S.T.; Davis, R.A. Coordinate transcriptional repression of liver fatty acid-binding protein and microsomal triglyceride transfer protein blocks hepatic very low density lipoprotein secretion without hepatosteatosis. J. Biol. Chem., 2006, 281(44), 33066-33077.
42. Murphy, K.G.; Dhillo, W.S.; Bloom, S.R. Gut peptides in the regulation of food intake and energy homeostasis. Endocr. Rev., 2006, 27(7), 719-727.
43. Tso, P.; Liu, M. Ingested fat and satiety. Physiol. Behav., 2004, 81(2), 275-287.
44. Thabuis, C.; Tissot-Favre, D.; Bezelgues, J.B.; Martin, J.C.; Cruz-Hernandez, C.; Dionisi, F.; Destaillats, F. Biological functions and metabolism of oleoylethanolamide. Lipids, 2008, 43(10), 887-894.
45. Aviello, G.; Matias, I.; Capasso, R.; Petrosino, S.; Borrelli, F.; Orlando, P.; Romano, B.; Capasso, F.; Di Marzo, V.; Izzo, A.A. Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. J Mol. Med., 2008, 86(4), 413-422.
46. Oveisi, F.; Gaetani, S.; Eng, K.T.; Piomelli, D. Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration. Pharmacol. Res., 2004, 49(5), 461-466.
47. Rodriguez de Fonseca, F.; Navarro, M.; Gomez, R.; Escuredo, L.; Nava, F.; Fu, J.; Murillo-Rodriguez, E.; Giuffrida, A.; LoVerme, J.; Gaetani, S.; Kathuria, S.; Gall, C.; Piomelli, D. An anorexic lipid mediator regulated by feeding. Nature, 2001, 414(6860), 209-212.
48. Qin, X.; Tso, P. The role of apolipoprotein AIV on the control of food intake. Curr. Drug Targets, 2005, 6(2), 145-151.
49. Tso, P.; Chen, Q.; Fujimoto, K.; Fukagawa, K.; Sakata, T. Apolipoprotein A-IV: a circulating satiety signal produced by the small intestine. Obes. Res., 1995, 3(Suppl. 5), 689S-695S.
50. Agellon, L.B.; Drozdowski, L.; Li, L.; Iordache, C.; Luong, L.; Clandinin, M.T.; Uwiera, R.R.; Toth, M.J.; Thomson, A.B. Loss of intestinal fatty acid binding protein increases the susceptibility of male mice to high fat diet-induced fatty liver. Biochim. Biophys. Acta, 2007, 1771(10), 1283-1288.
51. Agren, J.J.; Vidgren, H.M.; Valve, R.S.; Laakso, M.; Uusitupa, M.I. Postprandial responses of individual fatty acids in subjects homozygous for the threonine- or alanine-encoding allele in codon 54 of the intestinal fatty acid binding protein 2 gene. Am. J. Clin. Nutr., 2001, 73(1), 31-35.
52. Fisher, E.; Weikert, C.; Klapper, M.; Lindner, I.; Mohlig, M.; Spranger, J.; Boeing, H.; Schrezenmeir, J.; Doring, F. L-FABP T94A is associated with fasting triglycerides and LDL-cholesterol in women. Mol. Genet. Metab., 2007, 91(3), 278-284.
53. Robitaille, J.; Brouillette, C.; Lemieux, S.; Perusse, L.; Gaudet, D.; Vohl, M.C. Plasma concentrations of apolipoprotein B are modulated by a gene - diet interaction effect between the LFABP T94A polymorphism and dietary fat intake in French-Canadian men. Mol. Genet. Metab., 2004, 82(4), 296-303.
54. Brouillette, C.; Bosse, Y.; Perusse, L.; Gaudet, D.; Vohl, M.C. Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate. J. Hum. Genet., 2004, 49(8), 424-432.
55. Pratley, R.E.; Baier, L.; Pan, D.A.; Salbe, A.D.; Storlien, L.; Ravussin, E.; Bogardus, C. Effects of an Ala54Thr polymorphism in the intestinal fatty acid-binding protein on responses to dietary fat in humans. J. Lipid Res., 2000, 41(12), 2002-2008.
56. Baier, L.J.; Sacchettini, J.C.; Knowler, W.C.; Eads, J.; Paolisso, G.; Tataranni, P.A.; Mochizuki, H.; Bennett, P.H.; Bogardus, C.; Prochazka, M. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J. Clin. Invest., 1995, 95(3), 1281-1287.
57. Berthier, M.T.; Couillard, C.; Prud'homme, D.; Nadeau, A.; Bergeron, J.; Tremblay, A.; Despres, J.P.; Vohl, M.C. Effects of the FABP2 A54T mutation on triglyceride metabolism of viscerally obese men. Obes. Res., 2001, 9(11), 668-675.
58. Canani, L.H.; Capp, C.; Ng, D.P.; Choo, S.G.; Maia, A.L.; Nabinger, G.B.; Santos, K.; Crispim, D.; Roisemberg, I.; Krolewski, A.S.; Gross, J.L. The fatty acid-binding protein-2 A54T polymorphism is associated with renal disease in patients with type 2 diabetes. Diabetes, 2005, 54(11), 3326-3330.
59. Storch, J.; Corsico, B. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu. Rev. Nutr., 2008, 28, 73-95.
60. Furuhashi, M.; Hotamisligil, G.S. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov., 2008, 7(6), 489-503.